RabMAb

Anti-p53 (phospho S6)抗体[Y179] (ab32132)

概述

  • 产品名称Anti-p53 (phospho S6)抗体[Y179]
    参阅全部 p53 一抗
  • 描述
    兔单克隆抗体[Y179] to p53 (phospho S6)
  • 特异性ab32132 detects p53 phosphorylation on Serine 6. Predicted to react with p53 beta and gamma isoform, based on sequence homology.
  • 经测试应用适用于: WB, IHC-P, IPmore details
    不适用于: Flow Cyt or ICC/IF
  • 种属反应性
    与反应: Human
  • 免疫原

    within Human p53 aa 1-100 (phospho S6). The exact sequence is proprietary.
    Database link: P04637

  • 阳性对照
    • WB: MCF7 cell lysate. IHC-P: human urinary bladder carcinoma.
  • 常规说明

    This product is a recombinant rabbit monoclonal antibody.

     

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

性能

相关产品

应用

Our Abpromise guarantee covers the use of ab32132 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB 1/1000 - 1/5000. Detects a band of approximately 53 kDa (predicted molecular weight: 44 kDa).
IHC-P Use at an assay dependent concentration.
IP 1/100.
  • 应用说明Is unsuitable for Flow Cyt or ICC/IF.
  • 靶标

    • 功能Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
    • 组织特异性Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
    • 疾病相关Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
      Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
      Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
      Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
      Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980].
      Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
      Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.
    • 序列相似性Belongs to the p53 family.
    • 结构域The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.
    • 翻译后修饰Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
      Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.
      Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
      May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
      Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
      Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
      Sumoylated by SUMO1.
    • 细胞定位Cytoplasm; Cytoplasm. Nucleus. Nucleus > PML body. Endoplasmic reticulum. Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2; Nucleus. Cytoplasm. Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli; Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells; Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm; Nucleus. Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cytoplasm following cell stress.
    • Information by UniProt
    • 数据库链接
    • 别名
      • Antigen NY-CO-13 antibody
      • BCC7 antibody
      • Cellular tumor antigen p53 antibody
      • FLJ92943 antibody
      • LFS1 antibody
      • Mutant tumor protein 53 antibody
      • p53 antibody
      • p53 tumor suppressor antibody
      • P53_HUMAN antibody
      • Phosphoprotein p53 antibody
      • Tp53 antibody
      • Transformation related protein 53 antibody
      • TRP53 antibody
      • Tumor protein 53 antibody
      • Tumor protein p53 antibody
      • Tumor suppressor p53 antibody
      see all

    Anti-p53 (phospho S6) antibody [Y179] 图像

    • All lanes : Anti-p53 (phospho S6) antibody [Y179] (ab32132) at 1/1000 dilution

      Lane 1 : HepG2 whole cell lysate - untreated
      Lane 2 : HepG2 whole cell lysate - treated with Etopside

      Lysates/proteins at 10 µg per lane.

      Secondary
      Peroxidase-conjugated goat anti-rabbit IgG at 1/1000 dilution

      Predicted band size : 44 kDa
      Observed band size : 53 kDa (why is the actual band size different from the predicted?)


      Exposure time : 10 seconds

      Blocking and dilution buffer: 5% NFDM/TBST.

    • All lanes : Anti-p53 (phospho S6) antibody [Y179] (ab32132) at 1/500 dilution

      Lane 1 : DMSO treated HCT116 cell line
      Lane 2 : 10 µM irinotecan (CPT-11) treated HCT116 cell line for 24 hours

      Lysates/proteins at 20 µg per lane.

      Secondary
      Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 680) (ab175772) at 1/1000 dilution
      Developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 44 kDa


      Exposure time : 3 minutes

      This image is courtesy of an Abreview submitted by Christian Marx

      Blocking: 1 hour at room temperature with 5% Milk in TBST.

      Diluent: 2% Milk in TBST

      13% SDS-PAGE gel used.

       

      Secondary antibody - goat anti-rabbit Alexa Fluor 680

      See Abreview

    • All lanes : Anti-p53 (phospho S6) antibody [Y179] (ab32132) at 1/5000 dilution

      Lane 1 : MCF7 cell lysate, non-treated
      Lane 2 : MCF7 cell lysate, treated with Actinomycin D for 3 hours
      Lane 3 : MCF7 cell lysate, treated with Actinomycin D for 6 hours
      Lane 4 : MCF7 cell lysate, treated with Actinomycin D for 18 hours


      Predicted band size : 44 kDa
      Observed band size : 53 kDa (why is the actual band size different from the predicted?)
    • Immunohistochemical analysis of paraffin-embedded human urinary bladder carcinoma using ab32132 at 1/250 dilution.
    • ab32132 showing positive staining in Lung adenocarcinoma tissue.

    • ab32132 showing positive staining in Breast carcinoma tissue.

    • ab32132 showing positive staining in Colonic adenocarcinoma tissue.

    Anti-p53 (phospho S6) antibody [Y179] (ab32132)参考文献

    This product has been referenced in:
    • Gaber N  et al. Fetal reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during cardiac differentiation. Am J Pathol 183:720-34 (2013). IHC-P . Read more (PubMed: 23871585) »

    See 1 Publication for this product

    Product Wall

    Application Western blot
    Loading amount 20 µg
    Gel Running Conditions Reduced Denaturing (13%)
    Sample Human Cell lysate - whole cell (HCT116 human colon carcinoma cell line)
    Specification HCT116 human colon carcinoma cell line
    Treatment DMSO (Ctl) and 10 ´M irinotecan (CPT-11) treatment for 24 hrs
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Mr. Christian Marx

    Verified customer

    提交于 Nov 03 2014

    Application Western blot
    Loading amount 30 µg
    Gel Running Conditions Reduced Denaturing (4-12% gradient)
    Sample Human Cell lysate - whole cell (HCT116 human colon carcinoma cell line)
    Specification HCT116 human colon carcinoma cell line
    Treatment 20 ´M etoposide, 4 ´M doxorubicin for 16 hrs
    Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Dr. Oliver Maddocks

    Verified customer

    提交于 Apr 25 2014

    Application Western blot
    Sample Human Purified protein (immunopurified wild-type and S6A p53 protein)
    Loading amount 1e+006 cells
    Specification immunopurified wild-type and S6A p53 protein
    Gel Running Conditions Reduced Denaturing
    Blocking step (agent) for 30 minute(s) · Concentration: 100% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    提交于 Sep 11 2009

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"